Investors looking for exposure to artificial intelligence infrastructure are increasingly moving past the largest chipmakers toward specialized suppliers in the ecosystem. AEHR (Aehr Test Systems) provides semiconductor test and burn-in equipment used to validate AI processors, while AXTI (AXT, Inc.) manufactures compound semiconductor substrates, including indium phosphide, that enable high-speed optical connectivity inside data centers. This comparison is relevant for growth-oriented traders weighing two different points of leverage to the same AI build-out — one tied to equipment capacity and the other to a scarce specialty material — each with distinct momentum, valuation, and risk profiles. When I reviewed the latest filings, I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Aehr Test Systems designs wafer-level and package-level test and burn-in systems that screen semiconductor devices for early reliability failures. Its FOX and Sonoma platforms are used primarily by makers of AI processors, silicon photonics components, and power semiconductors. In recent weeks, AEHR reported a sharp financial inflection, with quarterly revenue roughly tripling year over year to a record and the company swinging from a net loss to a profit. Management also raised its full-year revenue outlook, supported by record bookings and a backlog in the range of roughly $100 million.
Despite the strong operating results, the stock has been volatile, having declined significantly from its recent highs even as it retained large gains on a year-to-date basis. Sentiment has been shaped by both enthusiasm around AI-related demand and concern over valuation, given a price-to-sales (P/S) ratio far above industry norms, plus meaningful insider selling. Analysts have maintained generally bullish ratings with price targets above recent levels, but the shares' premium valuation leaves limited room for disappointment.
AXT, Inc. produces compound and single-element semiconductor substrates — chiefly indium phosphide (InP), gallium arsenide (GaAs), and germanium (Ge) — used in fiber optics, 5G infrastructure, and data-center connectivity. In recent weeks, AXTI delivered record quarterly revenue, up more than 160% year over year, driven by exceptionally strong indium phosphide demand for AI data centers. GAAP gross margin expanded sharply, and the company reported solid net income alongside a backlog exceeding $500 million.
The stock has produced extraordinary gains over the past year but remains well below its 52-week high, reflecting a highly volatile ride. Sentiment has been shaped by China's export controls on indium phosphide substrates, which have both constrained shipments and, paradoxically, enhanced the strategic value of AXT's supply. Recent catalysts include a shift in its subsidiary's listing plans toward a Hong Kong IPO and analyst commentary citing favorable optics-industry developments. Capacity expansion, export-permit timing, and shareholder dilution from equity raises remain key watch items.
The two companies offer sharply contrasting business models. AEHR sells capital equipment, so its revenue depends on customers' willingness to expand test capacity, and it has historically served a concentrated set of large AI-processor and photonics buyers. AXTI, by contrast, supplies a consumable material — indium phosphide wafers — that underpins optical interconnects, giving it recurring pull-through as data-center build-outs scale.
On recent momentum, both have posted triple-digit year-over-year revenue growth, but AXTI currently shows stronger profitability metrics, including GAAP net income and much higher gross margins, whereas AEHR has only just returned to profitability on a quarterly basis. Risk profiles also differ: AEHR's principal risk is a premium valuation and customer concentration, while AXTI faces geopolitical and regulatory exposure tied to China's export controls, plus dilution from capital raises. Both are squarely exposed to AI-infrastructure spending, meaning a sector-wide pullback could pressure either name regardless of company-specific fundamentals. One thing that stands out when I cross-checked the data is how their backlogs highlight different stages of the supply chain.
Weighing trend consistency, profitability, backlog depth, and relative positioning, Tickeron's AI would currently lean toward AXTI in this comparison. The company's combination of GAAP profitability, sharply expanded margins, a backlog exceeding $500 million, and multiple analyst price targets well above recent trading levels points to a more durable, fundamentally supported growth trajectory. While AEHR presents a compelling equipment-leverage story with a record backlog and raised guidance, its elevated P/S ratio and recent drawdown introduce greater uncertainty into the trend picture. This assessment is probabilistic rather than definitive, and both stocks warrant close monitoring of catalysts and risk factors as conditions evolve. I’m watching this closely as new quarterly updates come in.
In my own research, I often turn to Tickeron’s AI Trading Bots to see how automated strategies are navigating similar names. The platform’s AI Trading Bots draw from hundreds of models that trade thousands of tickers, helping surface approaches with demonstrated relevance in the current environment without requiring manual screening of every option.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 50-day moving average for AEHR moved below the 200-day moving average on November 18, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AEHR as a result. In 73 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AEHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for AEHR entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AEHR's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for AEHR just turned positive on November 03, 2026. Looking at past instances where AEHR's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Following a +21.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where AEHR advanced for three days, in 243 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.970) is normal, around the industry mean (5.670). AEHR has a moderately low P/E Ratio (-232.913) as compared to the industry average of (68.795). Projected Growth (PEG Ratio) (0.927) is also within normal values, averaging (0.801). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (51.813) is also within normal values, averaging (27.897).
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. AEHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AEHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of burn-in and test equipment for semiconductor manufacturing
Industry ElectronicProductionEquipment